The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Open accessAbstract
Cancer immunotherapy based on genetically redirecting T cells has been used successfully to treat B cell malignancies 1-3. In this strategy, the T cell genome is modified by integration of viral vectors or transposons encoding chimaeric antigen receptors (CARs) that direct tumour cell killing. However, this approach is often limited by the extent of expansion and persistence of CAR T cells 4,5. Here we report mechanistic insights from studies of a patient with chronic lymphocytic leukaemia treated with CAR T cells targeting the CD19 protein. Following infusion of CAR T cells, anti-tumour activity was evident in the peripheral blood, lymph nodes and bone marrow; this activity was accompanied by complete remission. Unexpectedly, at the peak of the response, 94% of CAR T cells originated from a single clone in which lentiviral vector-mediated insertion of the CAR transgene disrupted the methylcytosine dioxygenase TET2 gene. Further analysis revealed a hypomorphic mutation in this patient's second TET2 allele. TET2-disrupted CAR T cells exhibited an epigenetic profile consistent with altered T cell differentiation and, at the peak of expansion, displayed a central memory phenotype. Experimental knockdown of TET2 recapitulated the potency-enhancing effect of TET2 dysfunction in this patient's CAR T cells. These findings suggest that the progeny of a single CAR T cell induced leukaemia remission and that TET2 modification may be useful for improving immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, the composition of autologous starting material from cancer patients is highly variable, influenced by patient age and defects due to underlying disease or pre-treatment with lymphotoxic agents (35-38).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [38]
Experimental — accuracy not yet measuredIn the citing paper
“T cells with a lentiviral integration disrupting TET2 showed strong preferential expansion at the peak of a patient’s response and likely contributed to this complete response to CAR T cell therapy.”
From Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function (2018) · cites this paper as Fraietta et al., 2018
In the citing paper
“The potential power of human primary T cell loss-of-function screens was recently demonstrated in a patient who received CAR T cell therapy for chronic lymphocytic leukemia (CLL) (Fraietta et al., 2018).”
From Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function (2018) · cites this paper as Fraietta et al., 2018
In the citing paper
“There is also a report of an exceptional response in a patient with CLL treated by infusion of chimeric antigen receptor (CAR) T-cells in which the CAR construct disrupted one copy of TET2, while the other copy had been previously mutated somatically 96.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationSummaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,837
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationTet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451
Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA
He, Y., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. (2011) · Science · doi:10.1126/science.1210944 · Cited by 2,776
Self-citationThe Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain
Kriaucionis, S., & Heintz, N. (2009) · Science · doi:10.1126/science.1169786 · Cited by 2,700
Ito, S., D’Alessio, A. C., Taranova, O., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,628
Cited by
Sorted by citations
Items 801–862 of 862
Immunotherapy for Primary Cancers of Central Nervous System
Maroufi, S. F., Mohammadi, E., Namvar, M., Iranmehr, A., Rezaei, N., & Hanaei, S. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_240-1
Guerrero-Murillo, M., Rill, A., Trincado, J. L., Bataller, Á., Ortiz‐Maldonado, V., Benítez‐Ribas, D., Español‐Rego, M., González, E. A., Martínez‐Cibrián, N., Marchese, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.23.576878
Cellular reprogramming by protein degradation: The next frontier in cancer immunotherapy
Ehinger, E., & Rao, A. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.01.004
Immune Cell Senescence and body Aging
Yoshimura, A. (2023) · Personalized Medicine Universe · doi:10.46459/pmu.2023006
Clinical Experience with CAR ‐T Cells for Treatment of B‐cell Lymphomas
Schuster, S. J., & Gribben, J. G. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch22
Liu, S., Wu, Z., Yuan, Y., Lin, Z., Zuo, D., Niu, Y., Li, B., Yuan, Y., & Qiu, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4485605/v1
Combination of CAR-T cell therapies with conventional anti-cancer therapies
Escobar, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00030-8
Modeling CAR Response at the Single-Cell Level Using Conditional Optimal TransportPreprint
Driessen, A., Born, J., Castellanos-Rueda, R., Reddy, S. T., & Rapsomaniki, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.11.622906
Self-citationConsiderations for nonclinical studies conducted to support the development of cellular therapies
Bolt, M. W., & Narayanan, P. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00011-0
Mazziotta, F., Martin, L. E., Eagan, D., Bar, M., Kinsella, S. M., Paulson, K. G., Voillet, V., Lahman, M. C., Hunter, D. S., Schmitt, T. M., et al. (2024) · medRxiv · doi:10.1101/2024.12.13.24318504
Rare biochemical & genetic conditions: clues for broader mechanistic insights
Mentis, A. A., & Dalamaga, Μ. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05652-6
“Molecular investigation revealed that nearly all CAR-T cells originated from a unique clone, where the insertion of the CAR transgene via viral delivery caused a frameshift mutation in the DNA methylation gene TET2 [15].”
Analytical Methods Shaping Cell Therapy Characterization
Amritha, L., Sudeshna, S., Rebecca, M., Rahamthulla, S., Egemen, T., & Amy, G. (2025) · doi:10.1002/9781394236145.ch14
Zeng, Q., Flemming, L., Chen, Y., Mazumder, T., Hammerlindl, H., Allen, G. M., Almeida, R., Williams, J. Z., Hernández-López, R. A., Eyquem, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.17.665438
Epigenetic Regulation of CD8 T Cell Differentiation
Passos, T. O., Oliveira, J. P., Melo, G. A., Calôba, C., & Pereira, R. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00283-0
Immunotherapy for Primary Cancers of Central Nervous System
Maroufi, S. F., Mohammadi, E., Namvar, M., Iranmehr, A., Rezaei, N., & Hanaei, S. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_240
Neoantigen-based TCR-T therapy in solid tumors
Feng, W., Wu, D., & Li, Y. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2025.11.001
Cheng, G., Wu, J., Ji, M., Hu, W., Wu, C., & Jiang, J. (2023) · Figshare · doi:10.6084/m9.figshare.24089380
Yang, C., Li, Y., Hu, Y., Li, Q., Lan, Y., & Li, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25157793
Xu, J., Wang, B., Yu, S.-H., Chen, S.-J., Yang, S.-S., Liu, R., Chen, L.-J., Hou, J., Chen, Z., Zhao, W.-H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25687360
Self-citationYang, C., Li, Y., Hu, Y., Li, Q., Lan, Y., & Li, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26677649
Yang, C., Li, Y., Hu, Y., Li, Q., Lan, Y., & Li, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25157322
Yang, C., Li, Y., Hu, Y., Li, Q., Lan, Y., & Li, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26677652
Yang, C., Li, Y., Hu, Y., Li, Q., Lan, Y., & Li, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26677655
Bracha, S., & Pollack, S. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-04454-9_4
Transcriptional and Epigenetic Regulation of T Cell States in Cancer
Ma, S., Hargreaves, D. C., & Kaech, S. M. (2026) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061325-042744
SAGA-Q: Gene Expression Differences Enable Detection of Retroviral Vectors with Mutagenic Potential
Mansel, F., Bastone, A. L., John-Neek, P., Fleischauer, J., Dziadek, V., Hagedorn, M., Schambach, A., & Rothe, M. (2026) · Human Gene Therapy · doi:10.1177/10430342251396966
“16 To ensure the safety of patients, appropriate preclinical biosafety assays are demanded by regulatory authorities to evaluate the genotoxic risk of RVs. Classically, genotoxicity assessment is performed in healthy, disease-speci fi c, or tumor-prone mouse models.”
TET2 -mutant clonal hematopoiesis prevents T-cell exhaustion and suppresses cancer metastasisPreprint
Le, A. N. T., Fujisawa, M., Campo, G., Nguyen, Y. T. M., Nguyen, T. B., Suma, S., Suehara, Y., Miura, F., Araki, H., Makishima, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.05.709727
Tosun, M., & Schenerman, M. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-21988-7.00028-1
Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer
Poluektova, V. B., Zuevskaya, S. N., Suvon, Y., Gulnihol, S., Turakulov, R., & Umirkulova, F. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04310-y
“Studies have shown that biallelic disruption of the TET2 gene reprograms the cell fate of CAR-T cells toward a central memory phenotype and enhances anti-tumor responses [31].”
Asiaticoside enhances the antitumor efficacy of MSLN-targeted CAR-T cells in ovarian cancer
Jiang, W., Cao, J., Li, Q., Xie, Y., Li, X., Pan, X., Yu, M., Zou, D., Sun, B., Yang, W., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08053-w
“Previous studies have established that exhausted T cells typically express high levels of inhibitory receptors and undergo specific phenotypic alterations [28, 29].”
Byrne, J. D. (2026) · Science · doi:10.1126/science.aef9968
Selezneva, A. V., Sosnovtseva, A. O., Starodubova, E. S., Antonov, D. O., Barkovskaya, V. I., & Киселев, С. Л. (2026) · Russian Journal of Genetics · doi:10.1134/s1022795425701741
Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple MyelomaPreprint
Talbot, A., Li, K., Lee, J. H. J., Lang, S., Liu, C., Kalter, N., Li, Z., Mortazavi, Y., Almudhfar, N., Muldoon, J. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.20.719660
Park, J. J., Avigan, Z. M., Dong, M. B., Nguyen, C. V., Guitart, J., Kotecha, R., Perica, K., Parekh, S., & Aleman, A. (2026) · Blood neoplasia · doi:10.1016/j.bneo.2026.100244
“…to be observed as new cases emerge and whether tissue-homing characteristics are related to molecular signatures imprinted during preexisting CH. 42-44 The study by Jain et al found that TET2 disruption can enhance the efficacy and proliferation of human CAR T-cells, but that the functional…”
Are entirely virus-free CAR T cells as good as lentiviral transduced universal cells?
Gough, O., Georgiadis, C., Preece, R., Kadirkamanathan, R., & Qasim, W. (2026) · Molecular Therapy · doi:10.64898/2026.04.30.721956
Kim, J.-H., Cho, H. J., & Lee, H. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154003 · Cited by 1
Enhancing the persistence of therapeutic T cells
Chen, G. M., & Fraietta, J. A. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.05.008
Self-citationChimeric Antigen Receptor-T Cells Fate after Infusion: Cellular Kinetics and Molecular Monitoring
Anelli, L., Cumbo, C., Minervini, A., Zagaria, A., Coccaro, N., Tarantini, F., Tota, G., Conserva, M. R., Redavid, I., Minervini, C. F., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.06.041
Liu, X., Cong, J., Xia, X., Wang, H., Yu, X., Zheng, Q., & Wang, L. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-014873
Self-citationWen, W., Li, X., Liu, T., Zhang, S., Sun, D., Zhao, X. M., Cheng, C.-Y., Zhang, L., Zhang, J., & Zhang, X.-B. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102955
Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy
Liu, W., Gu, J., Xie, C., Bing, D., Liu, M., & Zhang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1910092
Jurgens, E. M., Mitra, S., Herrera, K., Nemirovsky, D., Bready, B., Derkach, A., Hosszu, K., McAvoy, D. P., Firestone, R., Rajeeve, S., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aed0039 · Cited by 2
CAR-T in solid tumors: Obstacles and potential strategies
Ding, Z., Li, Y., & Huang, M. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.07.047
Zhan, Y., Hu, C., & Xiao, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1913968
Universal CAR-T cell therapy: mechanisms and evasion strategies of bidirectional immune rejection
Ding, L., Zhao, L., Zhang, M., Chen, T., & Guo, Z. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189690
Peh, C. R., Cui, Z., Besnard, M., Loh, K. L., Halim, H., Chang, J., Nguyen‐Dumont, T., Ooi, J. D., & Ting, Y. T. (2026) · Research Square · doi:10.21203/rs.3.rs-10544631/v1
Nakamura, N., Seo, H., Hamada, R., Kaneko, H., Kagoya, Y., & Ohta, S. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154569
Beyond CAR-T: Preventing and Treating Relapse in B-Cell Haematological Malignancies
Canichella, M., Abruzzese, E., Cefalo, M., Gianfelici, V., Mazzone, C., Trotta, G. E., Laureana, R., Cupelli, L., & Principe, M. I. D. (2026) · Cells · doi:10.3390/cells15181660
Targeting the Epigenetic–Immune Axes in Hematologic Malignancies
Pandita, R., & Lind, E. F. (2026) · Cancers · doi:10.3390/cancers18182985
“Carl June’s lab showed that in CLL, loss of TET2 can be beneficial for CAR-T cell function [277].”
In vivo CAR‑T cell therapy: mechanisms, clinical advances and optimization strategies
Li, Y., Wang, F., Li, J., Gao, H., Li, D., & Wang, W. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118491
CAR-T in vivo : quand le patient devient sa propre usine de production
Vilcot, F., Brugère, C.-A., Fuentealba, J., & Houot, R. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.07.016
Huang, L., Sheng, J., Chi, L., Xu, Y., & Wang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1966718
Self-citationExtended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma
Xu, J., Liu, L., Xie, W., Su, L., Wang, W., Li, C., Liu, Q., Kang, Y., Zhang, Y., Luo, W., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04704-z
Self-citationT cell receptor-engineered T cells for hepatocellular carcinoma: next steps and future perspectives
Li, Z., Shu, J., Zhang, Q., Su, S., Zhou, J., Luan, Y., Xu, J., Gu, J., & Huang, X. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00075-1
“…semi-random integration and variable transgene copy numbers [37]; (2) high manufacturing costs [38]; (3) the potential for insertional mutagenesis [39]; (4) a relatively constrained cargo capacity; and (5) the retention of endogenous TCR hemi-chains, which can generate mispaired heterodimers (α ′…”
Self-citationToward the next generation of CAR T cell therapies for cancer
Usta, D., & Mackall, C. L. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.005
Cytokine-Independent Proliferation of CAR-T cells: Bug or Feature?
Hu, P., Wirthlin, L., Carter, A. J., Dinsmore, J., Schoeder, B., Miltenyi, S., Schmitz, J., Assenmacher, M., Engels, B., Dash, P., et al. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.103037
From delivery to integration: CRISPR ‐mediated large insert gene editing in primary human T cells
Buttle, B., Verdon, D. J., & Sheppard, H. M. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70124
“21”
Metadata
- Authors
- Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., Hwang, Y., Gohil, M., Kulikovskaya, I., Nazimuddin, F., Gupta, M., Chen, F., Everett, J. K., Alexander, K. A., Lin-Shiao, E., Gee, M. H., Liu, X., Young, R. M., Ambrose, D., Wang, Y., Xu, J., Jordan, M. S., Marcucci, K. T., Levine, B. L., Garcia, K. C., Zhao, Y., Kalos, M., Porter, D. L., Kohli, R. M., Lacey, S. F., Berger, S. L., Bushman, F. D., June, C. H., & Melenhorst, J. J.
- Affiliations
- Abramson Cancer Center (US)
- University of Pennsylvania (US)
- State University of New York (US)
- University of Michigan (US)
- Stanford Medicine (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- June, Carl H.
- Melenhorst, J. Joseph
- ORCID
- Fraietta, Joseph A.
- Nobles, Christopher L.
- Sammons, Morgan A.
- Lundh, Stefan
- Carty, Shannon A.
- Reich, Tyler J.
- Cogdill, Alexandria P.
- Morrissette, Jennifer J. D.
- Gohil, Mercy
- Kulikovskaya, Irina
- Gupta, Minnal
- Chen, Fang
- Everett, John K.
- Alexander, Katherine A.
- Lin-Shiao, Enrique
- Gee, Marvin H.
- Liu, Xiaojun
- Young, Regina M.
- Wang, Yan
- Xu, Jun
- Jordan, Martha S.
- Levine, Bruce L.
- Zhao, Yangbing
- Kalos, Michael
- Porter, David L.
- Kohli, Rahul M.
- Lacey, Simon F.
- Berger, Shelley L.
- Bushman, Frederic D.
- June, Carl H.
- Melenhorst, J. Joseph
- Venue
- Nature
- Published
- 2018-05-30
- Volume
- 558
- Issue
- 7709
- Pages
- 307-312
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6320248
- OpenAlex
- W2804231581
- Cited by
- 862
- References
- 47
- Citations by year
- 2026: 69 · 2025: 117 · 2024: 126 · 2023: 111 · 2022: 105 · 2021: 116 · 2020: 107 · 2019: 86 · 2018: 25
- FWCI
- 31.32
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (T32CA009140, R01CA165206, R01CA078831, P01CA214278)
- National Institute of General Medical Sciences (R01GM118501)
- National Institute of Allergy and Infectious Diseases (U01AI104400, K08AI101008, R01AI104400, U19AI117950, R01AI082020, P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TET2, CD19, chimeric antigen receptor T cells, CAR T-cell therapy, chronic lymphocytic leukemia, DNA methylation, epigenetic reprogramming, T cell differentiation, central memory T cells, T cell expansion, B-cell malignancies
- MeSH terms
- Aged, Alleles, Cell Differentiation, Clinical Trials as Topic, Clone Cells, Humans, Immunotherapy, Male, Mutation, Recombinant Fusion Proteins, T-Lymphocytes, Leukemia, Lymphocytic, Chronic, B-Cell, Antigens, CD19, Transgenes, Adoptive Transfer, Epigenesis, Genetic, 5-Methylcytosine, Dioxygenases, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
